Diagnostic Cardiovascular Imaging Laboratory, University of California, Los Angeles, Peter V. Ueberroth Building Suite 3371, 10945 Le Conte Ave, Los Angeles, 90095-7206, CA, USA.
Department of Radiological Sciences, University of California, Los Angeles, Los Angeles, USA.
J Cardiovasc Magn Reson. 2019 Mar 11;21(1):17. doi: 10.1186/s12968-019-0528-5.
Although cardiovascular magnetic resonance venography (CMRV) is generally regarded as the technique of choice for imaging the central veins, conventional CMRV is not ideal. Gadolinium-based contrast agents (GBCA) are less suited to steady state venous imaging than to first pass arterial imaging and they may be contraindicated in patients with renal impairment where evaluation of venous anatomy is frequently required. We aim to evaluate the diagnostic performance of 3-dimensional (3D) ferumoxytol-enhanced CMRV (FE-CMRV) for suspected central venous occlusion in patients with renal failure and to assess its clinical impact on patient management.
In this IRB-approved and HIPAA-compliant study, 52 consecutive adult patients (47 years, IQR 32-61; 29 male) with renal impairment and suspected venous occlusion underwent FE-CMRV, following infusion of ferumoxytol. Breath-held, high resolution, 3D steady state FE-CMRV was performed through the chest, abdomen and pelvis. Two blinded reviewers independently scored twenty-one named venous segments for quality and patency. Correlative catheter venography in 14 patients was used as the reference standard for diagnostic accuracy. Retrospective chart review was conducted to determine clinical impact of FE-CMRV. Interobserver agreement was determined using Gwet's AC1 statistic.
All patients underwent technically successful FE-CMRV without any adverse events. 99.5% (1033/1038) of venous segments were of diagnostic quality (score ≥ 2/4) with very good interobserver agreement (AC1 = 0.91). Interobserver agreement for venous occlusion was also very good (AC1 = 0.93). The overall accuracy of FE-CMRV compared to catheter venography was perfect (100.0%). No additional imaging was required prior to a clinical management decision in any of the 52 patients. Twenty-four successful and uncomplicated venous interventions were carried out following pre-procedural vascular mapping with FE-CMRV.
3D FE-CMRV is a practical, accurate and robust technique for high-resolution mapping of central thoracic, abdominal and pelvic veins and can be used to inform image-guided therapy. It may play a pivotal role in the care of patients in whom conventional contrast agents may be contraindicated or ineffective.
虽然心血管磁共振静脉造影(CMRV)通常被认为是成像中心静脉的首选技术,但常规 CMRV 并不理想。钆基对比剂(GBCA)不太适合稳态静脉成像,而更适合初次通过动脉成像,并且在需要经常评估静脉解剖结构的肾功能损害患者中可能存在禁忌。我们旨在评估 3 维(3D)铁氧体增强磁共振静脉造影(FE-CMRV)在肾功能衰竭患者中怀疑中央静脉阻塞的诊断性能,并评估其对患者管理的临床影响。
在这项经机构审查委员会批准和符合 HIPAA 规定的研究中,52 例连续的成年肾功能损害且怀疑静脉阻塞的患者(47 岁,IQR 32-61;29 名男性)接受了 FE-CMRV,方法是在输注铁氧体后进行呼吸暂停、高分辨率、3D 稳态 FE-CMRV 通过胸部、腹部和骨盆进行。两名盲法审阅者独立对 21 个命名静脉段的质量和通畅性进行评分。在 14 例患者中,采用对比剂导管静脉造影作为诊断准确性的参考标准。回顾性病历审查用于确定 FE-CMRV 的临床影响。使用 Gwet 的 AC1 统计量确定观察者间一致性。
所有患者均成功进行了技术上可行的 FE-CMRV,无任何不良事件。99.5%(1033/1038)的静脉段具有诊断质量(评分≥2/4),观察者间一致性非常好(AC1=0.91)。静脉闭塞的观察者间一致性也非常好(AC1=0.93)。与导管静脉造影相比,FE-CMRV 的总体准确性为完美(100.0%)。在 52 例患者中的任何一例中,在做出临床管理决策之前,均无需进行额外的影像学检查。24 例成功且无并发症的静脉介入治疗在进行血管术前 FE-CMRV 血管成像后进行。
3D FE-CMRV 是一种实用、准确且强大的技术,可用于高分辨率成像中心胸、腹和盆腔静脉,并可用于指导治疗。它可能在常规对比剂可能禁忌或无效的患者的治疗中发挥关键作用。